Immune responses to respiratory syncytial virus (RSV) vaccines tended to fall short in older people with weakened immunity, a ...

India has ramped up monitoring for cases of human metapneumovirus (HMPV) amid concerns around a reported outbreak in ...

Johns Hopkins Medicine researchers have shown that people 60 years or older with weakened immunity do not respond as strongly ...

A Massachusetts mother is warning other parents about the respiratory risks this season as her young has been hospitalized ...

The respiratory syncytial virus (RSV) vaccine may not protect older adults who are immunocompromised as much as their healthier peers, according to new research.

Northern provinces in China have been hit with a surge of HMPV infections in the last three weeks. This has forced the centre ...

Approximately 40% of participants did not seroconvert or achieve a conservative neutralization threshold post-vaccination.

Dr. Vivek Nangia is an internationally renowned Interventional Pulmonologist, with over two decades of rich clinical ...

The study followed 38 immunocompromised adults, aged 64 to 72, who received either the Arexvy or Abrysvo RSV vaccine. Researchers found that people aged 60 and older who are immunocompromised ...

Recent reports from Malaysia reveal a 45% increase in human metapneumovirus (HMPV) cases in 2024 compared to 2023. The ...

It parallels earlier work done at the center to better understand how the immune systems of people who are immunocompromised respond to vaccines against SARS-CoV-2, the virus that causes COVID-19.

In 38 immunocompromised persons who received either the RSVPreF3-AS01E (RSVA-AS01E; Arexvy) or RSVpreF (Abrysvo) vaccine, preF IgG antibody titers rose a median 4.21-fold by 4 weeks -- with 61% of ...